NCT07239141 Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective Surgery
| NCT ID | NCT07239141 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mario Zamudio |
| Condition | Airway Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 252 participants |
| Start Date | 2025-12-04 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 252 participants in total. It began in 2025-12-04 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test two video laryngoscopes that help doctors place a breathing tube during surgery. A breathing tube is needed for people who receive general anesthesia so they can breathe safely. Video laryngoscopes use a small camera to give a better view of the throat and vocal cords, which may help the tube go in on the first try. The purpose of this research is to find out if a Colombian device called Laringocel® works as well as the widely used international device C-MAC D-Blade® (Karl Storz). If Laringocel® performs similarly, it could be a more affordable option for hospitals with limited resources. 252 adults (126 in each group) who need elective surgery at Alma Máter Hospital de Antioquia (Medellín, Colombia) will take part. Each participant will be randomly assigned, like flipping a coin, to have their breathing tube placed with either Laringocel® or C-MAC D-Blade®. Only trained anesthesiologists will perform the procedure. The study will look at: Main goal: how often the tube goes in correctly on the first attempt. Other goals: overall success within 3 attempts, how well the airway is seen, how long the intubation takes, how satisfied the doctor is with the device, and possible side effects such as sore throat, dental injury, or oral injury. Participation will not change the usual care people receive during anesthesia. Both devices are already approved for clinical use. Risks are the same as with any standard intubation, and participants will be checked after surgery for any problems. By comparing these two devices, researchers hope to learn if Laringocel® can provide safe and effective intubation at lower cost, improving access to advanced airway tools.
Eligibility Criteria
Inclusion Criteria: * Patients 18 years of age or older * Patients scheduled for elective surgery under general anesthesia * Patients requiring single-lumen orotracheal intubation * Patients compliant with the anesthetic indication and standard preoperative fasting requirements Exclusion Criteria: * Patients with an anticipated difficult airway (more than two anatomical risk factors for difficult airway) * Patient refusal to participate in the study via informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07239141 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Airway Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07239141 currently recruiting?
Yes, NCT07239141 is actively recruiting participants. Contact the research team at gabrielr.munozm@udea.edu.co for enrollment information.
Where is the NCT07239141 trial being conducted?
This trial is being conducted at Medellín, Colombia.
Who is sponsoring the NCT07239141 clinical trial?
NCT07239141 is sponsored by Mario Zamudio. The trial plans to enroll 252 participants.